Weekly Digest – May 2025 Weekly Digest – May 2025 23 May 2025: ASCENT-03: Trodelvy demonstrates highly statistically significant & clinically meaningful improvement in progression free survival in patients with first-line metastatic TNBC who are not candidates for checkpoint inhibitors […]
Weekly Digest – May 2025 Weekly Digest – May 2025 30 May 2025: Astellas enters exclusive license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage ADC Targeting CLDN18.2 Astellas Pharma has secured exclusive worldwide rights (excluding Greater China) to […]
Weekly Digest – May 2025 Weekly Digest – May 2025 19 May 2025: Blenrep (Belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple Myeloma GSK’s Blenrep in combination with bortezomib plus dexamethasone (BVd) and in combination with pomalidomide […]
Weekly Digest – May 2025 Weekly Digest – May 2025 19 May 2025: Zai Lab receives U.S. FDA fast track designation for ZL-1310, a DLL3-targeted ADC, for treatment of extensive-stage small cell Lung cancer The FDA has granted fast track […]
Weekly Digest – May 2025 Weekly Digest – May 2025 19 May 2025: CPO301 granted the third fast track designation by US FDA for the treatment of adult patients with NSCLC CPO301 (SYS6010 in China) has received its third fast […]
Weekly Digest – May 2025 Weekly Digest – May 2025 22 May 2025: Avenzo Therapeutics announces FDA clearance of Investigational New Drug application for AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate Avenzo Therapeutics received FDA clearance for its […]
Weekly Digest – May 2025 Weekly Digest – May 2025 22 May 2025: Fourth NDA for Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT) accepted by the Center for Drug Evaluation The NMPA’s Center for Drug Evaluation (CDE) accepted a new application […]
Weekly Digest – May 2025 Weekly Digest – May 2025 09 May 2025: RemeGen’s Disitamab vedotin gains approval in China for its third indication making it the first ADC approved for HER2-positive advanced Breast cancer with liver metastasis globally China’s […]
Weekly Digest – May 2025 Weekly Digest – May 2025 14 May 2025: U.S. FDA Approves EMRELIS (Telisotuzumab vedotin) for adults with previously treated advanced Non-Small Cell Lung Cancer (NSCLC) with high c-Met protein overexpression The FDA granted accelerated approval […]
Weekly Digest – May 2025 Weekly Digest – May 2025 14 May 2025: ADC Therapeutics announces presentation of LOTIS-7 clinical trial data at the European Hematology Association 2025 congress (EHA2025) and the 18th international conference on malignant lymphoma (ICML) LOTIS-7 […]
